Targeted CML therapy: controlling drug resistance, seeking cure

Tumour stem cells and drug resistance

2005 • 3,535 citations

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

2004 • 1,785 citations

The molecular biology of chronic myeloid leukemia

2000 • 1,596 citations

Granulocyte–Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML

2004 • 1,472 citations

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

2005 • 1,435 citations

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

2003 • 1,253 citations

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

2004 • 1,231 citations

In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

2005 • 1,039 citations

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity

2004 • 950 citations

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

2002 • 925 citations

Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase

2003 • 843 citations

Dynamics of chronic myeloid leukaemia

2005 • 838 citations

MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors

2004 • 685 citations

Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors

2003 • 658 citations

Active transport of imatinib into and out of cells: implications for drug resistance

2004 • 650 citations

Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL

2003 • 624 citations

Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche

2004 • 616 citations

Leukaemia stem cells and the evolution of cancer-stem-cell research

2005 • 604 citations

The biology of CML blast crisis

2004 • 584 citations

Therapeutic implications of cancer stem cells

2003 • 562 citations

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

2005 • 556 citations

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

2005 • 491 citations

Regulation of the c-Abl and Bcr–Abl tyrosine kinases

2004 • 467 citations

Drug resistance in cancer: Principles of emergence and prevention

2005 • 417 citations

The BCR-ABL Story: Bench to Bedside and Back

2004 • 395 citations

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

2005 • 385 citations

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

2004 • 339 citations

Strategies to overcome resistance to targeted protein kinase inhibitors

2004 • 332 citations

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

2005 • 319 citations

Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization

2005 • 279 citations

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

2005 • 227 citations

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

2004 • 219 citations

BCR/ABL activates mdm2 mRNA translation via the La antigen

2003 • 218 citations

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

2004 • 213 citations

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML

2004 • 196 citations

Mechanisms and implications of imatinib resistance mutations in BCR-ABL

2003 • 189 citations

Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment

2004 • 167 citations

Punish the parent not the progeny

2004 • 147 citations

Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease

2005 • 136 citations

Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate

2003 • 128 citations

Mechanisms controlling pathogenesis and survival of leukemic stem cells

2004 • 125 citations

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR and FIP1L1-PDGFR in vitro and in vivo

2005 • 115 citations

[Tumor stem cells and drug resistance].

2007 • 106 citations

Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib

2005 • 102 citations

Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia

2005 • 101 citations

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor

2005 • 93 citations

The FIP1L1-PDGFR?? kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia

2003 • 81 citations

Structural Basis for the Cytoskeletal Association of Bcr-Abl/c-Abl

2005 • 77 citations

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

2005 • 72 citations

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.

2003 • 69 citations

Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era

2004 • 59 citations

Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease

2004 • 46 citations

A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002

2005 • 36 citations

A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): Results from CA180002

2005 • 33 citations

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)

2005 • 30 citations

Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia

2004 • 24 citations

Leukemic Stem Cells of Chronic Phase CML Patients Consistently Display Very High BCR-ABL Transcript Levels and Reduced Responsiveness to Imatinib Mesylate in Addition to Generating a Rare Subset That Produce Imatinib Mesylate-Resistant Differentiated Progeny.

2004 • 18 citations

Activity of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, in imatinib-resistant bcr-abl positive lymphoid malignancies

2005 • 11 citations